2025 U.S. Generic & Biosimilar Medicines Savings Report
Generics comprised 90% of all prescriptions filled, but only 12% of prescription spending. Brand drugs made up only 10% of prescriptions filled but added up to 88% of the total drug spend.
The Generics Industry Wants a Healthy America
Low-cost generics and biosimilars positively impact the health of American patients. Plus, over the past decade, widespread adoption has saved the U.S. healthcare system $3.1 trillion. But this success story is in jeopardy.
AAM White Paper: Hatch-Waxman Turns 40
“Since the introduction of this law, we have all seen incredible savings. But even as we celebrate the success of forty years of Hatch-Waxman, those savings, the increased patient access, and a model of generic adoption that leads the world, are at risk.” — David Gaugh, Interim President & CEO, AAM.
Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?
Avalere analysis finds Part D prescription drug plans continue to increase patient copays for generics by moving them to higher tiers.
Generic and biosimilar medicines make it easier and more affordable for patients to live healthier lives.
